Welcome to our dedicated page for Modular Med news (Ticker: MODD), a resource for investors and traders seeking the latest updates and insights on Modular Med stock.
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company focused on insulin delivery technology for people with diabetes. Its news flow centers on the design and development of user-friendly, affordable patch pumps, regulatory milestones for its Pivot tubeless insulin delivery system, and capital markets activity related to funding its operations.
Company announcements frequently highlight progress on the Pivot insulin delivery system, which Modular Medical describes as a next-generation, tubeless, removable three milliliter patch pump aimed at adult "almost-pumpers" who have not adopted traditional insulin pumps. News items include updates on Institutional Review Board (IRB) approvals for in-house studies, feasibility and insulin-use trials under simulated real-world conditions, and the submission of a 510(k) premarket filing to the U.S. Food and Drug Administration. The company also reports that the Pivot insulin delivery system is not currently cleared for sale by the FDA.
Investors following MODD news will also see disclosures about manufacturing readiness, such as validation of the Pivot controller manufacturing line for human-use production and steps toward high-volume manufacturing. Additional coverage includes progress toward CE Mark certification under EU MDR 2017/745, including ISO 13485:2016 quality management audits, as the company prepares for potential international commercialization.
Financial and listing-related updates form another important part of Modular Medical’s news stream. The company issues press releases on public offerings of common stock and warrants, warrant exercises and inducement agreements, and Nasdaq notices regarding minimum bid price compliance and related extensions. For those tracking MODD, this news page provides a centralized view of regulatory, operational, and financing developments affecting the company’s insulin delivery technology business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Modular Medical, Inc. (NASDAQ:MODD) has updated its progress on the MODD-1 insulin pump, transitioning to a full commercial version designed with a tier-1 medical product manufacturer. This new version aims to resolve prior material compatibility issues, enhance cost-effectiveness, and streamline usability. The company anticipates submitting the device for FDA approval in the quarter ending December 31, 2023, following the arrival of key production equipment and subsequent testing. The initiative seeks to make insulin delivery technology more accessible and user-friendly for diabetes patients.